# A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

> **NCT02963506** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 303 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **OTHER:** Placebo
- **DRUG:** Bimekizumab

## Key facts

- **NCT ID:** NCT02963506
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2017-10
- **Final completion:** 2018-08
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02963506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02963506, "A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02963506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*